Polaris Greystone Financial Group LLC Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Polaris Greystone Financial Group LLC trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 63.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,338 shares of the medical research company’s stock after selling 54,958 shares during the quarter. Polaris Greystone Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $8,760,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 1.2% in the second quarter. Vanguard Group Inc. now owns 30,670,985 shares of the medical research company’s stock valued at $9,007,455,000 after purchasing an additional 378,260 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Thermo Fisher Scientific by 1.4% during the 2nd quarter. BlackRock Inc. now owns 27,643,905 shares of the medical research company’s stock worth $8,118,461,000 after acquiring an additional 392,227 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Thermo Fisher Scientific by 2.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,139,325 shares of the medical research company’s stock worth $5,033,477,000 after acquiring an additional 395,830 shares in the last quarter. FMR LLC boosted its stake in shares of Thermo Fisher Scientific by 33.5% during the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock worth $3,167,647,000 after acquiring an additional 2,900,868 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Thermo Fisher Scientific by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,559,667 shares of the medical research company’s stock worth $1,045,404,000 after acquiring an additional 102,504 shares in the last quarter. 88.18% of the stock is currently owned by institutional investors.

In related news, Director Jim P. Manzi sold 1,833 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the transaction, the director now owns 28,592 shares in the company, valued at approximately $7,803,614.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 2,271 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the transaction, the chief executive officer now owns 283,502 shares of the company’s stock, valued at approximately $84,483,596. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,104 shares of company stock valued at $15,418,539. Insiders own 0.45% of the company’s stock.

Shares of TMO traded up $5.30 during mid-day trading on Wednesday, hitting $277.23. 916,209 shares of the company were exchanged, compared to its average volume of 1,589,164. Thermo Fisher Scientific Inc. has a 1-year low of $208.34 and a 1-year high of $305.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The company has a 50 day moving average of $287.05 and a 200-day moving average of $280.62. The stock has a market cap of $111.60 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 1.91 and a beta of 1.13.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm had revenue of $6.32 billion during the quarter, compared to the consensus estimate of $6.31 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.25 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Monday, September 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

TMO has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price on the stock in a research note on Wednesday, June 12th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Credit Suisse Group reissued a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Barclays set a $330.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, Needham & Company LLC increased their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $303.17.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Does the discount rate affect the economy?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.